<?xml version="1.0" encoding="UTF-8"?>
<ref id="cam41388-bib-0007">
 <label>7</label>
 <mixed-citation publication-type="journal" id="cam41388-cit-0007">
  <string-name>
   <surname>Green</surname>, 
   <given-names>M. D.</given-names>
  </string-name>, 
  <string-name>
   <given-names>H.</given-names>
   <surname>Koelbl</surname>
  </string-name>, 
  <string-name>
   <given-names>J.</given-names>
   <surname>Baselga</surname>
  </string-name>, 
  <string-name>
   <given-names>A.</given-names>
   <surname>Galid</surname>
  </string-name>, 
  <string-name>
   <given-names>V.</given-names>
   <surname>Guillem</surname>
  </string-name>, 
  <string-name>
   <given-names>P.</given-names>
   <surname>Gascon</surname>
  </string-name>, et al. 
  <year>2003</year>
  <article-title>A randomized double‐blind multicenter phase III study of fixed‐dose single‐administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy</article-title>. 
  <source>Ann. Oncol.</source>
  <volume>14</volume>:
  <fpage>29</fpage>–
  <lpage>35</lpage>.
  <pub-id pub-id-type="pmid">12488289</pub-id>
 </mixed-citation>
</ref>
